DexCom’s (DXCM) Buy Rating Reiterated at Canaccord Genuity Group

DexCom (NASDAQ:DXCM)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a report issued on Tuesday, Benzinga reports. They currently have a $145.00 price target on the medical device company’s stock. Canaccord Genuity Group’s price objective suggests a potential upside of 29.53% from the stock’s current price.

DXCM has been the topic of several other reports. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. UBS Group boosted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Redburn Atlantic initiated coverage on DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective on the stock. Finally, Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $139.33.

DexCom Trading Down 0.2 %

DXCM stock opened at $111.94 on Tuesday. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom has a 12-month low of $74.75 and a 12-month high of $142.00. The stock has a market cap of $44.52 billion, a price-to-earnings ratio of 72.22, a PEG ratio of 2.73 and a beta of 1.16. The business’s 50-day moving average is $117.11 and its 200 day moving average is $124.40.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, sell-side analysts anticipate that DexCom will post 1.78 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares of the company’s stock, valued at $8,611,765. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP Michael Jon Brown sold 629 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares of the company’s stock, valued at $8,611,765. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold a total of 4,112 shares of company stock valued at $480,861 over the last quarter. 0.30% of the stock is owned by company insiders.

Institutional Trading of DexCom

Large investors have recently modified their holdings of the stock. Bank of New Hampshire acquired a new stake in DexCom in the first quarter valued at $1,508,000. abrdn plc raised its stake in DexCom by 21.1% in the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock valued at $47,221,000 after buying an additional 66,348 shares in the last quarter. Cerity Partners LLC raised its stake in DexCom by 5,791.0% in the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock valued at $57,574,000 after buying an additional 456,097 shares in the last quarter. Eagle Asset Management Inc. raised its stake in DexCom by 21.5% in the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock valued at $217,929,000 after buying an additional 310,728 shares in the last quarter. Finally, Alberta Investment Management Corp raised its stake in DexCom by 27.0% in the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock valued at $40,123,000 after buying an additional 68,723 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.